RHYTHM PHARMACEUTICALS, INC. (RYTM) Operating Margin
- Operating margin · 12 months: Value -83.62%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -83.62% | Operating income / revenue. Period ending 2026-06-30. $-200.63M ÷ $239.92M × 100 ≈ -83.62% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -200.63M USD | Operating Income (Loss) |
| Revenue | 239.92M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 26.39M USD | Cost of Goods and Services Sold |
| Research and development | 173.21M USD | Research and Development Expense |
| Selling, general and administration | 240.95M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-200.63M | $239.92M | $26.39M | $173.21M | $240.95M | -83.62% |
| 2026-03-31 | $-197.37M | $217.16M | $23.00M | $172.09M | $219.44M | -90.89% |
| 2025-12-31 | $-192.02M | $189.76M | $19.49M | $167.34M | $194.94M | -101.19% |
| 2025-09-30 | $-186.21M | $174.33M | $18.48M | $166.47M | $175.59M | -106.81% |
| 2025-06-30 | $-177.44M | $156.29M | $16.81M | $158.38M | $158.54M | -113.53% |
| 2025-03-31 | $-172.62M | $136.86M | $14.21M | $146.26M | $149.01M | -126.13% |
| 2024-12-31 | $-265.50M | $130.13M | $13.37M | $237.96M | $144.30M | -204.04% |
| 2024-09-30 | $-265.51M | $112.53M | $12.81M | $226.68M | $138.55M | -235.95% |
| 2024-06-30 | $-265.59M | (m) | $11.40M | $222.32M | $133.66M | (m) |
| 2024-03-31 | $-271.71M | (m) | $10.69M | $225.67M | $127.28M | (m) |
| 2023-12-31 | $-184.36M | $77.43M | $9.30M | $134.95M | $117.53M | -238.10% |
| 2023-09-30 | $-185.19M | (m) | $7.10M | $128.61M | $111.47M | (m) |
| 2023-06-30 | $-180.50M | (m) | $5.18M | $116.15M | $102.93M | (m) |
| 2023-03-31 | $-179.00M | (m) | $3.32M | $114.06M | $95.22M | (m) |
| 2022-12-31 | $-179.16M | (m) | $2.13M | $108.63M | $92.03M | (m) |
| 2022-09-30 | $-188.04M | (m) | $1.34M | $116.66M | $86.71M | (m) |
| 2022-06-30 | $-193.02M | (m) | $1.07M | $123.08M | $82.28M | (m) |
| 2022-03-31 | $-188.35M | (m) | $825.00K | $116.73M | $75.42M | (m) |
| 2021-12-31 | $-170.06M | (m) | $599.00K | $104.13M | $68.49M | (m) |
| 2021-09-30 | $-154.14M | (m) | (m) | $94.51M | $60.61M | (m) |
| 2021-06-30 | $-144.19M | (m) | (m) | $89.96M | $54.39M | (m) |
| 2021-03-31 | $-135.67M | (m) | (m) | $87.86M | $47.85M | (m) |
| 2020-12-31 | $-136.57M | (m) | (m) | $90.45M | $46.13M | (m) |
| 2020-09-30 | $-135.73M | (m) | (m) | $93.31M | $42.42M | (m) |
| 2020-06-30 | $-138.55M | (m) | (m) | $96.88M | $41.67M | (m) |
| 2020-03-31 | $-150.78M | (m) | (m) | $109.19M | $41.59M | (m) |
| 2019-12-31 | $-146.00M | (m) | (m) | $109.45M | $36.55M | (m) |
| 2019-09-30 | $-138.93M | (m) | (m) | $103.40M | $35.52M | (m) |
| 2019-06-30 | $-121.06M | (m) | (m) | $87.54M | $33.53M | (m) |
| 2019-03-31 | $-91.94M | (m) | (m) | $60.81M | $31.12M | (m) |
| 2018-12-31 | $-78.42M | $0.00 | (m) | $50.34M | $28.08M | (m) |
| 2018-09-30 | $-62.25M | (m) | (m) | $38.23M | $24.02M | (m) |
| 2018-06-30 | $-51.29M | (m) | (m) | $33.49M | $17.80M | (m) |
| 2018-03-31 | $-43.02M | (m) | (m) | $30.31M | $12.72M | (m) |
| 2017-12-31 | $-32.41M | $0.00 | (m) | $22.89M | $9.52M | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-25.91M | $0.00 | (m) | $19.59M | $6.31M | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-10.57M | (m) | (m) | $7.15M | $3.42M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |